Type II Hyperlipidemia

1
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Akros Pharma
Akros PharmaNJ - Princeton
1 program
1
JTT-705 600 mg and pravastatin 40 mgPhase 21 trial
Active Trials
NCT00688896Completed155Est. Mar 2004

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Akros PharmaJTT-705 600 mg and pravastatin 40 mg

Clinical Trials (1)

Total enrollment: 155 patients across 1 trials

NCT00688896Akros PharmaJTT-705 600 mg and pravastatin 40 mg

Efficacy and Safety Study of JTT-705 in Combination With Pravastatin 40 mg in Patients With Type II Hyperlipidemia

Start: Jun 2002Est. completion: Mar 2004155 patients
Phase 2Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space